Bioage Labs, INC Schedule 13G passive stakes

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 2,390,605 shares, representing 5.38% of BioAge Labs, Inc.'s common stock.

Khosla Ventures and affiliates have filed an amendment to their Schedule 13G, reporting a decrease in beneficial ownership of BioAge Labs, Inc. to below the 5% threshold.

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.51% in BioAge Labs, Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.03% of BioAge Labs, Inc.'s common stock as of March 31, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 5.69% beneficial ownership stake in BioAge Labs, Inc. common stock as of December 31, 2025.

Kristen Fortney, a key insider at BioAge Labs, Inc., has increased her beneficial ownership to 7.2% of the company's common stock as of December 31, 2025.

ADAR1 Capital Management and Daniel Schneeberger report beneficial ownership of 5.4% of BioAge Labs' common stock as of June 30, 2025.

Cormorant Asset Management, LP and Bihua Chen report a 5.97% beneficial ownership stake in BioAge Labs, Inc., holding 2,140,605 shares.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of BioAge Labs, Inc. common stock to below 5% as of December 31, 2024.

Cormorant Asset Management, LP and Bihua Chen have disclosed a passive 7.34% beneficial ownership stake in BioAge Labs, Inc. as of December 31, 2024.